Difference between revisions of "Carboplatin, Pemetrexed, Pembrolizumab in advanced or metastatic non-small cell lung cancer"
Jump to navigation
Jump to search
m |
m |
||
| Line 31: | Line 31: | ||
|} | |} | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
| − | *[[Carboplatin (Paraplatin)]] AUC 5 IV over 15 to 60 minutes once on day 1 | + | *[[Carboplatin (Paraplatin)]] AUC 5 IV over 15 to 60 minutes once on day 1 '''given last''' |
| − | *[[Pemetrexed (Alimta)]] 500 mg/m<sup>2</sup> IV over 10 minutes once on day 1 | + | *[[Pemetrexed (Alimta)]] 500 mg/m<sup>2</sup> IV over 10 minutes once on day 1 '''given second''' |
| − | *[[Pembrolizumab (Keytruda)]] 200 mg IV over 30 minutes once on day 1, '''given at least 30 minutes prior to chemotherapy''' | + | *[[Pembrolizumab (Keytruda)]] 200 mg IV over 30 minutes once on day 1, '''given first, at least 30 minutes prior to chemotherapy''' |
====Supportive medications==== | ====Supportive medications==== | ||
Revision as of 04:30, 12 May 2017
Regimen in use at
Regimen
| Study | Evidence | ORR | Comparator | Efficacy |
| Langer et al. 2016 (KEYNOTE-021) | Randomized Phase II | 71% | Carboplatin & Pemetrexed +/- pemetrexed maintenance | Superior ORR |
Chemotherapy
- Carboplatin (Paraplatin) AUC 5 IV over 15 to 60 minutes once on day 1 given last
- Pemetrexed (Alimta) 500 mg/m2 IV over 10 minutes once on day 1 given second
- Pembrolizumab (Keytruda) 200 mg IV over 30 minutes once on day 1, given first, at least 30 minutes prior to chemotherapy
Supportive medications
- "Premedication with folic acid, vitamin B12, and corticosteroids was administered according to local guidelines."
21-day cycle for 4 cycles. Followed by pembolizumab +/- pemetrexed maintenance therapy
References
- Langer CJ, Gadgeel SM, Borghaei H, Papadimitrakopoulou VA, Patnaik A, Powell SF, Gentzler RD, Martins RG, Stevenson JP, Jalal SI, Panwalkar A, Yang JC, Gubens M, Sequist LV, Awad MM, Fiore J, Ge Y, Raftopoulos H, Gandhi L; KEYNOTE-021 investigators.. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. Lancet Oncol. 2016 Nov;17(11):1497-1508 link to original article contains verified protocol supplementary appendix; PubMed